InsiderCluster

NUVL

NasdaqGM

Nuvalent Inc

$123.96
123.96 ()

Price

No chart data available.

Key statistics

Previous close$0.00
Day range123.95 – 123.99
52-week range71.13 – 123.99
Volume3.09M
CurrencyUSD
ExchangeNasdaqGM
Crowd sentiment
88Bullish

Insider activity

SEC EDGAR ↗
Open-mkt buys
0
$0.00
Open-mkt sells
0
$0.00
Net flow
+0
0 open-market trades

Showing 94 recent filings. None are open-market buys/sells — recent activity is grants, option exercises, gifts or tax withholding (which don't signal conviction).

InsiderTypeSharesPriceValueDate
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition8.3M$124.00$1,029,103,900.002026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition8.3M$124.00$1,029,103,900.002026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition650K$124.00$80,600,000.002026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Code U5.15K$124.00$638,104.002026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Code U5.15K$124.00$638,104.002026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition3.44K$124.00$427,056.002026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition2.72M$124.00$336,985,748.002026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition2.72M$124.00$336,985,748.002026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition43K2026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition43K2026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition20K2026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition20K2026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition15K2026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition15K2026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition3.79K2026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition3.79K2026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition4.15K2026-07-15
Flynn James E
Director, 10% Owner, Director by Deputization
Disposition4.15K2026-07-15
Meyers Michael L.
Director
Code U5.15K$124.00$638,104.002026-07-15
Meyers Michael L.
Director
Disposition3.44K2026-07-15
Meyers Michael L.
Director
Disposition8.36K2026-07-15
Meyers Michael L.
Director
Disposition40K2026-07-15
Meyers Michael L.
Director
Disposition15K2026-07-15
Meyers Michael L.
Director
Disposition3.79K2026-07-15
Meyers Michael L.
Director
Disposition4.15K2026-07-15
Balcom Alexandra
Chief Financial Officer
Code U44.43K$124.00$5,509,692.002026-07-15
Balcom Alexandra
Chief Financial Officer
Disposition41.1K2026-07-15
Balcom Alexandra
Chief Financial Officer
Grant / award14.35K$0.002026-07-15
Balcom Alexandra
Chief Financial Officer
Disposition14.35K2026-07-15
Balcom Alexandra
Chief Financial Officer
Disposition131.64K2026-07-15
Balcom Alexandra
Chief Financial Officer
Disposition8.02K2026-07-15
Balcom Alexandra
Chief Financial Officer
Disposition22.93K2026-07-15
Balcom Alexandra
Chief Financial Officer
Disposition84.2K2026-07-15
Balcom Alexandra
Chief Financial Officer
Disposition33.65K2026-07-15
Balcom Alexandra
Chief Financial Officer
Disposition37.5K2026-07-15
Balcom Alexandra
Chief Financial Officer
Disposition17.5K2026-07-15
Srivastava Sapna
Director
Code U5.15K$124.00$638,104.002026-07-15
Srivastava Sapna
Director
Disposition3.44K2026-07-15
Srivastava Sapna
Director
Disposition68.5K2026-07-15
Srivastava Sapna
Director
Disposition20K2026-07-15
Srivastava Sapna
Director
Disposition15K2026-07-15
Srivastava Sapna
Director
Disposition3.79K2026-07-15
Srivastava Sapna
Director
Disposition4.15K2026-07-15
Oliger Christy J.
Director
Code U1.32K$124.00$164,176.002026-07-15
Oliger Christy J.
Director
Disposition6.09K2026-07-15
Oliger Christy J.
Director
Disposition6.12K2026-07-15
Squarer Ron
Director
Disposition6.28K2026-07-15
Squarer Ron
Director
Disposition4.42K2026-07-15
Turner Christopher Durant
Chief Medical Officer
Code U31.53K$124.00$3,909,720.002026-07-15
Turner Christopher Durant
Chief Medical Officer
Disposition41.1K2026-07-15
Turner Christopher Durant
Chief Medical Officer
Grant / award14.35K$0.002026-07-15
Turner Christopher Durant
Chief Medical Officer
Disposition14.35K2026-07-15
Turner Christopher Durant
Chief Medical Officer
Disposition303.11K2026-07-15
Turner Christopher Durant
Chief Medical Officer
Disposition2.84K2026-07-15
Turner Christopher Durant
Chief Medical Officer
Disposition107K2026-07-15
Turner Christopher Durant
Chief Medical Officer
Disposition144.2K2026-07-15
Turner Christopher Durant
Chief Medical Officer
Disposition47.5K2026-07-15
Turner Christopher Durant
Chief Medical Officer
Disposition37.5K2026-07-15
Turner Christopher Durant
Chief Medical Officer
Disposition17.5K2026-07-15
Noci Darlene
Chief Development Officer
Code U17.02K$124.00$2,110,108.002026-07-15
Noci Darlene
Chief Development Officer
Disposition41.1K2026-07-15
Noci Darlene
Chief Development Officer
Grant / award14.35K$0.002026-07-15
Noci Darlene
Chief Development Officer
Disposition14.35K2026-07-15
Noci Darlene
Chief Development Officer
Disposition2162026-07-15
Noci Darlene
Chief Development Officer
Disposition6.09K2026-07-15
Noci Darlene
Chief Development Officer
Disposition15.11K2026-07-15
Noci Darlene
Chief Development Officer
Disposition21.26K2026-07-15
Noci Darlene
Chief Development Officer
Disposition81.33K2026-07-15
Noci Darlene
Chief Development Officer
Disposition33.65K2026-07-15
Noci Darlene
Chief Development Officer
Disposition37.5K2026-07-15
Noci Darlene
Chief Development Officer
Disposition17.5K2026-07-15
Lane Benjamin
See Remarks
Code U21.09K$124.00$2,615,408.002026-07-15
Lane Benjamin
See Remarks
Disposition29.43K2026-07-15
Lane Benjamin
See Remarks
Grant / award7.12K$0.002026-07-15
Lane Benjamin
See Remarks
Disposition7.12K2026-07-15
Lane Benjamin
See Remarks
Disposition7312026-07-15
Lane Benjamin
See Remarks
Disposition8.33K2026-07-15
Lane Benjamin
See Remarks
Disposition17.85K2026-07-15
Lane Benjamin
See Remarks
Disposition15.05K2026-07-15
Lane Benjamin
See Remarks
Disposition12.03K2026-07-15
Lane Benjamin
See Remarks
Disposition8K2026-07-15
Lane Benjamin
See Remarks
Disposition19K2026-07-15
Pelish Henry E.
Chief Scientific Officer
Code U22.39K$124.00$2,776,732.002026-07-15
Pelish Henry E.
Chief Scientific Officer
Disposition41.1K2026-07-15
Pelish Henry E.
Chief Scientific Officer
Grant / award14.35K$0.002026-07-15
Pelish Henry E.
Chief Scientific Officer
Disposition14.35K2026-07-15
Pelish Henry E.
Chief Scientific Officer
Disposition3.26K2026-07-15
Pelish Henry E.
Chief Scientific Officer
Disposition2.11K2026-07-15
Pelish Henry E.
Chief Scientific Officer
Disposition8.31K2026-07-15
Pelish Henry E.
Chief Scientific Officer
Disposition9.9K2026-07-15
Pelish Henry E.
Chief Scientific Officer
Disposition21.07K2026-07-15
Pelish Henry E.
Chief Scientific Officer
Disposition18.6K2026-07-15
Pelish Henry E.
Chief Scientific Officer
Disposition37.5K2026-07-15
Pelish Henry E.
Chief Scientific Officer
Disposition17.5K2026-07-15

Source: SEC EDGAR Forms 4/4A (CIK 1861560). Click an insider to open the original filing.

Social sentiment

88
Bullish

Volume-weighted across live social sources

StockTwitsLIVE
7 bull881 bear
Recent posts
@SellasgpsCurativeBAT11· StockTwits3d ago

$RVMD $SLS $GSK $NUVL Buy out can happens anytime given the overwhelming success? Ex: GSK closed the Nuvalent, Inc. acquisition on 15th July. Jideytro had FDA approval days later. That timing isn't a credit to fast integration; it's a feature of how these deals actually work that doesn't get discussed enough: the regulatory clock doesn't reset on a change of ownership. The ARROS-1 data was already filed. The review was already running. GSK wasn't buying a bet on whether the science would work, Nuvalent had already de-risked that. It was buying a position in an outcome that was, by closing, close to locked in. That's a meaningfully different logic than the one usually applied to biotech M&A. Buying pre-Phase Ill is a science bet. Buying at this stage is a timing and distribution bet, the value is in being the company selling the drug the day it clears, not in the probability that it clears at all. Here we are waiting for data but big pharma due to patent cliff has other plans. ✌️🙏❤️‍🩹

@wyoming2020· StockTwitsJul 23

$NUVL $GSK rectal approval next

@ConsulHorkos· StockTwitsJul 23

$NUVL congrats on your approval post BO

@SellasgpsCurativeBAT11· StockTwitsJul 20

$SLS $GSK $NUVL GSK just paid $10.6 BILLION. That's what GSK is paying to acquire Nuvalent (NUVL). Big pharmaceuticals are in a buying frenzy with $380 Billion in patent expirations within next 2 years.

@TwongStocks· StockTwitsJul 13

$NUVL Equity Corporate Actions Alert #2026 - 493 Information Regarding the Merger of Nuvalent, Inc. (NUVL) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-493 The tender offer by GSK Plc (GSK-NYSE) to acquire all of the outstanding Class A Common Stock of Nuvalent, Inc. (NUVL) is scheduled to expire one minute after 11:59 p.m. ET, on July 14, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on July 15, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on July 14, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (July 15th) and will be suspended effective July 16, 2026. At closing, NUVL shareholders will receive $124.00 for each share held.

@MikeyMcDermott· StockTwitsJul 9

The other thing is $GSK $NUVL deal clears HSR tonight at 11:59PM EST. Tender offer closes July 14 and deal will probably close July 15. Maybe that also opens up something with $SPRO and/or $ANAB Pretty busy over in London with all these things in motion.

@MikeyMcDermott· StockTwitsJul 4

$SPRO $GSK $NUVL wilmer hale, leerink, mintz, pwc, ropes & gray ... someone in Boston knows something imo CLOSE BIZ -- then go watch the Boston Pops at the Hatch Shell Ampitheatre on the Charles River Esplanade .... if it isn't too hot

@MikeyMcDermott· StockTwitsJul 4

$SPRO Leerink advised $GSK in the $NUVL deal https://investors.nuvalent.com/2026-06-09-GSK-enters-agreement-to-acquire-Nuvalent,-Inc

@De12· StockTwitsJun 26

$NUVB Getting Co Ready For buyout like $NUVL Look at that Volume!!

@De12· StockTwitsJun 25

$NUVB Getting this baby ready for Sale! like $NUVL loading the Dip!

@De12· StockTwitsJun 25

$NUVB Paying back loan plus 550 Million Cash on Hand, Getting Co Ready for $NUVL type Buyout?

@IN0V8· StockTwitsJun 19

$NUVL that 1 was spot on 🎯 https://stocktwits.com/IN0V8/message/655100043

Latest news

Get insider-buy alerts

Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.